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Although it is well established that misfolding of the cellular prion protein (PrPC)
into the β-sheet-rich, aggregated scrapie conformation (PrPSc) causes a variety of
transmissible spongiform encephalopathies (TSEs), the physiological roles of PrPC are still
incompletely understood. There is accumulating evidence describing the roles of PrPC in
neurodegeneration and neuroinflammation. Recently, we identified a functional regulation
of NMDA receptors by PrPC that involves formation of a physical protein complex between
these proteins. Excessive NMDA receptor activity during conditions such as ischemia
mediates enhanced Ca2+ entry into cells and contributes to excitotoxic neuronal death.
In addition, NMDA receptors and/or PrPC play critical roles in neuroinflammation and
glial cell toxicity. Inhibition of NMDA receptor activity protects against PrPSc-induced
neuronal death. Moreover, in mice lacking PrPC, infarct size is increased after focal
cerebral ischemia, and absence of PrPC increases susceptibility of neurons to NMDA
receptor-dependent death. Recently, PrPC was found to be a receptor for oligomeric
beta-amyloid (A Cβ) peptides, suggesting a role for PrP in Alzheimer’s disease (AD). Our
recent findings suggest that Aβ peptides enhance NMDA receptor current by perturbing
the normal copper- and PrPC-dependent regulation of these receptors. Here, we review
evidence highlighting a role for PrPC in preventing NMDA receptor-mediated excitotoxicity
and inflammation. There is a need for more detailed molecular characterization of
PrPC-mediated regulation of NMDA receptors, such as determining which NMDA receptor
subunits mediate pathogenic effects upon loss of PrPC-mediated regulation and identifying
PrPC binding site(s) on the receptor. This knowledge will allow development of novel
therapeutic interventions for not only TSEs, but also for AD and other neurodegenerative
disorders involving dysfunction of PrPC.
Keywords: NMDA receptor, cellular prion protein, excitotoxicity, neuroinflammation, ischemia, beta-amyloid,
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INTRODUCTION
Misfolding of the cellular prion protein (PrPC) into the β-sheet-
rich, aggregate-prone scrapie conformation (PrPSc) is well known
to result in several progressive and often fatal diseases termed
prionopathies. This group of disorders, also known as transmissi-
ble spongiform encephalopathies (TSEs), includes scrapie, bovine
spongiform encephalopathy (BSE, or mad cow disease), and the
human diseases Creutzfeld–Jakob disease, Gerstmann-Straussler-
Scheinker syndrome, fatal familial insomnia, and Kuru (Aguzzi
et al., 2008). PrPSc aggregation and formation of amyloid-like
plaques disrupt neuronal physiology, and most TSEs involve
eventual loss of neurons (Aguzzi et al., 2008). Although much
work has been done investigating the deleterious effects of mis-
folded/aggregated prion proteins, the physiological roles of PrPC
remain incompletely understood.
Mature PrPC is a glycoprotein that is anchored to the extra-
cellular leaflet of the plasma membrane through a carboxyl
(C)-terminal glycosylphosphatidylinositol (GPI) anchor. Initially,
PrPC is synthesized as a precursor polypeptide (254 amino
acids for mouse PrPC) containing an amino (N)-terminal sig-
nal sequence that directs PrPC to the endoplasmic reticulum
and is post-translationally cleaved, and a C-terminal GPI anchor
sequence that is removed and replaced with a GPI anchor
(Figure 1; Biasini et al., 2012). The N-terminal portion of PrPC
is intrinsically unstructured, contains the octarepeat region, and
has multiple copper binding sites both within and outside of the
octarepeat region (Figure 1; Klewpatinond et al., 2008; Stanyon
et al., 2014). The PrPC N-terminus also contains sites for binding
of oligomeric β-amyloid (Aβ) peptides (Figure 1; Lauren et al.,
2009; Chen et al., 2010). In contrast to the N-terminus, the
C-terminus of PrPC is globular in structure, with three α-helical
and two short β-strand regions, and is the location of two
asparagine residues that undergo glycosylation (Figure 1; Biasini
et al., 2012). In addition, PrPC can undergo physiological cleav-
age of different types: α-cleavage in the vicinity of residue 109
(mouse sequence) generates N1 and C1 fragments; β-cleavage in
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FIGURE 1 | Schematic representation of PrPC. Numbering of amino acid
residues corresponds to the mouse PrPC sequence. Shown are the locations
of histidine (H) residues that bind copper ions (residues 60, 68, 76, 84, 95,
110), the amino (N)-terminal signal peptide (SP; residues 1–22), β-amyloid
oligomer (Aβ) binding regions (residues 23–27, 95–110), the octapeptide
repeat region (OR; residues 51–90), the central hydrophobic domain (HD;
residues 111–130), α-helical regions (α; residues 143–152, 171–191, 199–221),
β-sheet regions (β; residues 127–129, 166–168), sites of asparagine (N)-linked
glycosylation (residues 180, 196), and the carboxyl (C)-terminal
glycosylphosphatidylinositol (GPI) signal peptide (GSP; residues 231–254).
the vicinity of residue 90 (mouse sequence) produces N2 and
C2 fragments; and cleavage at the GPI anchor releases full-length
PrPC into the extracellular environment (Altmeppen et al., 2013;
McDonald et al., 2014). However, recent data from McDonald
and co-workers using recombinant mouse PrPC reveal that cleav-
age of PrPC is quite complex, generating a number of different
N1, C1, N2, and C2 fragments (McDonald et al., 2014), although
the biological functions of these cleavage products remain to be
determined.
PrPC interacts with and signals through many different cell
surface proteins, including the α7 nicotinic acetylcholine recep-
tor (Beraldo et al., 2010), metabotropic glutamate receptors
mGluR1 (Beraldo et al., 2011) and mGluR5 (Beraldo et al.,
2011; Um et al., 2013), kainate receptor GluR6/7 (Carulla et al.,
2011), and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid (AMPA) receptor subunits GluA1 (Watt et al., 2012) and
GluA2 (Kleene et al., 2007; Watt et al., 2012). Furthermore, Aβ
oligomers can bind to PrPC and signal through mGluR5 to acti-
vate Fyn kinase (Um et al., 2013), and an Aβ-PrPC-mGluR5
pathway is also involved in facilitation of long-term depression
(LTD) (Hu et al., 2014). The diversity of signaling mediated by
PrPC highlights the need for a better understanding of how the
interaction of PrPC with its binding partners is regulated in both
physiological and pathological conditions.Work from our labora-
tory revealed that PrPC also interacts with N-methyl-D-aspartate
(NMDA) receptors; PrPC-deficient mice display increased NMDA
receptor-dependent neuronal excitability and are more suscep-
tible to NMDA-induced excitotoxicity (Khosravani et al., 2008).
Here, we briefly review properties of the NMDA receptor and
focus on evidence supporting a role for PrPC in preventing
NMDA receptor-mediated excitotoxicity, a process that may con-
tribute to the pathogenesis of a variety of disorders including
ischemic stroke, Alzheimer’s disease (AD), Huntington’s disease,
and epilepsy (Lai et al., 2014; Parsons and Raymond, 2014).
Similar mechanisms may be involved in PrPSc-induced toxicity
(Müller et al., 1993; Riemer et al., 2008; Resenberger et al., 2011).
NMDA RECEPTOR CHARACTERISTICS
Glutamate is the major excitatory transmitter in the mam-
malian central nervous system (CNS), and it exerts its actions
by binding to a variety of different receptor proteins. Glutamate
receptors (GluRs) are divided into two families, ionotropic and
metabotropic. Metabotropic GluRs are G protein-coupled recep-
tors, while ionotropic GluRs are ion channels. There are three
types of ionotropic GluRs, namely AMPA, kainate, and NMDA
receptors (Mayer, 2005).
NMDA receptors are cation channels that mediate entry of
Na+ and Ca2+ ions and are activated by the co-agonists gluta-
mate (or NMDA) and glycine or D-serine. Activation of NMDA
receptors thus contributes to the excitatory postsynaptic poten-
tial (EPSP), as well as both long-term potentiation (LTP) and
LTD (Bartlett andWang, 2013). In addition to co-agonist binding,
activation of NMDA receptors requires membrane depolariza-
tion to remove the Mg2+ ion block of the channel pore that
occurs at resting membrane potentials. NMDA receptors are het-
erotetrameric channels formed by the assembly of two obligatory
GluN1 and two GluN2/GluN3 subunits. GluN1 subunits contain
the binding site for glycine, while glutamate binds to GluN2 sub-
units. To date, there are seven known NMDA receptor subunits:
GluN1, GluN2A-GluN2D, and GluN3A-GluN3B, with alternative
splicing of GluN1 and GluN3 subunits generating further diver-
sity (Paoletti et al., 2013). GluN3 subunits also bind glycine, and
thus NMDA receptors containing only GluN1 and GluN3 sub-
units give rise to “glycine-only” receptors that cannot be activated
by glutamate or NMDA (Chatterton et al., 2002; Pina-Crespo
et al., 2010). Identity of the GluN2 subunits that combine with
GluN1 subunits to form the tetrameric channel dictates NMDA
receptor properties, such as activation and deactivation kinet-
ics, ion conductance, and affinity for glutamate (Cull-Candy and
Leszkiewicz, 2004). Pharmacological characterization using lig-
ands for specific GluN2 subunits allows differentiation of receptor
subtypes (Wyllie et al., 2013).
NMDA receptor localization can be synaptic, perisynaptic,
extrasynaptic, or even presynaptic, with receptor activity at each
location coupling to specific cellular events (Corlew et al., 2008;
Hardingham, 2009; Hardingham and Bading, 2010; Paoletti et al.,
2013). In general, activation of synaptic NMDA receptors acti-
vates pro-survival signaling, while extrasynaptic NMDA recep-
tor activity mediates pro-death signaling (Hardingham, 2009;
Hardingham and Bading, 2010). Thus, while NMDA receptors
mediate key physiological functions such as learning and mem-
ory under normal conditions, they also play a role in glutamate
excitotoxicity, which can occur in response to ischemia (Lau
and Tymianski, 2010) and is involved in many neurodegener-
ative conditions, including AD (Parsons and Raymond, 2014).
In these abnormal situations, excessive glutamate can spill over
from synaptic to extrasynaptic sites, thus activating not only the
desired synaptically-localized NMDA receptors, but also those
receptors located extrasynaptically. Because NMDA receptors are
highly permeable to Ca2+ ions, this overstimulation leads to
enhanced Ca2+ influx that ultimately can be fatal to cells (Lau
and Tymianski, 2010). NMDA receptors are found not only in
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neurons, but also in oligodendrocytes and myelin, and ischemia
can cause NMDA receptor-dependent damage to both myelin
and oligodendrocyte processes (Karadottir et al., 2005; Salter and
Fern, 2005; Micu et al., 2006). Hence, tight regulation of NMDA
receptor activity is of extreme importance in maintaining physio-
logical signaling while preventing excitotoxicity. NMDA receptor
activity is regulated by a number of different mechanisms, one
of which involves an intrinsic desensitization mechanism that
results in termination of channel activity even in the prolonged
presence of glutamate, a process that is potently regulated by
the receptor co-agonist glycine (Mayer et al., 1989). Recently, we
demonstrated that the absence of PrPC enhances NMDA recep-
tor glycine affinity, leading to persistent NMDA receptor activity
upon prolonged agonist application (You et al., 2012), which
likely underlies the greater susceptibility of PrPC-null neurons
to NMDA receptor-mediated damage and dysfunction (Rangel
et al., 2007; Khosravani et al., 2008; Gadotti and Zamponi, 2011;
Gadotti et al., 2012; You et al., 2012; Fleisch et al., 2013).
PrPC AS A REGULATOR OF NMDA RECEPTORS
In support of a role for PrPC in preventing NMDA receptor
hyperactivity, data from our and other laboratories reveal that
NMDA receptor activity is enhanced when PrPC is absent. Our
work using mouse hippocampal slices showed that the enhanced
neuronal excitability in PrPC-null neurons can be reduced by
the NMDA receptor blocker aminophosphonovaleric acid (APV),
and that NMDA receptor-mediated miniature excitatory postsy-
naptic currents (mEPSCs) recorded from cultured hippocampal
neurons from PrPC-null mice had significantly larger ampli-
tudes and longer decay times than those recorded from wild-
type neurons (Khosravani et al., 2008). In this study we also
showed that NMDA application resulted in whole-cell currents
with a prolonged time course of deactivation in cultured PrPC-
null hippocampal neurons that could be restored to wild-type
levels by ectopic expression of mouse PrPC and mimicked by
reducing PrPC expression in cultured wild-type hippocampal
neurons. Co-immunoprecipitation experiments demonstrated
that PrPC and GluN2D subunits were found in the same pro-
tein complex, and immunofluorescent staining of hippocampal
neurons showed co-localization of these two proteins. Indeed,
the properties of the NMDA-evoked currents we observed in
PrPC-null neurons in this study appeared to resemble those of
heterologously-expressed GluN2D-containing NMDA receptors
(Cull-Candy and Leszkiewicz, 2004). Furthermore, siRNA knock-
down of GluN2D expression dramatically accelerated NMDA
receptor current deactivation kinetics and reduced current ampli-
tude. Taken together, these observations point to an upregulation
of GluN2D-containing NMDA receptor activity in the absence of
PrPC. However, it is also possible that activity of NMDA receptors
containing other subunits is altered by the lack of PrPC, produc-
ing GluN2D-like deactivation kinetics. Finally, in support of a role
for PrPC in protecting against NMDA receptor-mediated toxicity,
we observed significantly more cell death in response to NMDA
treatment of PrPC-null hippocampal cultures than in wild-type
cultures, and that focal injection of NMDA into the hippocampus
resulted in a lesion of significantly greater size in PrPC-null mice
than in wild-type mice (Khosravani et al., 2008). This increase
in NMDA receptor activity not only gives rise to an increased
susceptibility of neurons to cell death, but also affects other phys-
iological processes that are linked to NMDA receptor function.
For example, NMDA receptors are important for the transmis-
sion of pain signals at the spinal level. Consequently, in models of
inflammatory and neuropathic pain, we found enhanced nocicep-
tive responses in PrPC-null mice that could be restored to control
levels by MK-801 (Gadotti and Zamponi, 2011). It is also known
that NMDA receptors play a role in depressive-like behavior at the
level of the hippocampus. Consistent with this notion, we found
that PrPC-null mice displayed increased depressive-like behavior
that could be abrogated by NMDA receptor blockers (Gadotti
et al., 2012).
It is well established that PrPC is a copper-binding protein,
with up to six copper ions binding to histidine residues in
the N-terminal region both within (mouse PrPC residues 60,
68, 76, and 84) and outside of (mouse PrPC residues 95 and
110) the octarepeat region (Figure 1; Klewpatinond et al., 2008;
Quintanar et al., 2013). In addition, copper may bind to histi-
dine residues 176 and 186 (mouse sequence) in the C-terminus
of PrPC (Quintanar et al., 2013), and recent evidence shows that
copper can bind to the N-terminal amino group of PrPC (Stanyon
et al., 2014). Occupancy of these copper sites is known to alter
PrPC structure (Qin et al., 2000; Thakur et al., 2011; Younan
et al., 2011; Quintanar et al., 2013), and thus likely its interac-
tions with other protein partners. The ability to examine NMDA
receptor activity as an indirect readout of the interaction of the
receptors with PrPC has provided interesting insights into the
roles of the copper binding sites for PrPC function. Under nor-
mal circumstances, NMDA receptors undergo desensitization in
the prolonged presence of glutamate or NMDA, and this process
is modulated by the co-agonist glycine (Mayer et al., 1989). In
cultured mouse hippocampal neurons lacking PrPC, the desensi-
tization kinetics appear to be slowed such that a non-desensitizing
current is observed (You et al., 2012). In wild-type neurons,
copper chelation using bathocuproine sulfonate (BCS) or cupri-
zone induced a persistent NMDA current similar to that seen
in PrPC-null neurons (You et al., 2012). Acute treatment with
phosphatidylinositol-specific phospholipase C (PI-PLC), which
enzymatically removes proteins such as PrPC that are linked to the
extracellular leaflet of the plasmamembrane via GPI anchors, also
induced a persistent NMDA-dependent current in rat hippocam-
pal neurons that was similar to both the current seen with copper
chelation and to that recorded from PrPC-null mouse hippocam-
pal neurons (You et al., 2012). Moreover, PI-PLC treatment did
not alter the steady-state NMDA current in PrPC-null neurons,
indicating that the enzymatic cleavage did not measurably affect
other potential regulatory proteins (You et al., 2012). Experiments
investigating the effect of glycine concentration on steady-state
NMDA current revealed that at a given glycine concentration, a
higher level of steady-state current was seen in neurons lacking
PrPC than in wild-type neurons; a similar effect was seen upon
copper chelation (You et al., 2012). In rat hippocampal cultures,
copper chelation induced cell death that could be prevented by
NMDA receptor inhibition or re-addition of excess copper (You
et al., 2012). Taken together, these results indicate that copper ions
modulate NMDA receptors by virtue of their interactions with
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PrPC. Furthermore, these findings suggests that copper ions are
key regulators of NMDA receptor function, thus adding another
layer of metal ion regulation of these receptors in addition to the
well described role of zinc ions.
Further support for PrPC-mediated regulation of NMDA
receptor activity comes from a study using zebrafish with a tar-
geted mutation of the prp2 gene encoding the zebrafish prion
protein PrP2, which has characteristics similar to mammalian
PrPC (Fleisch et al., 2013). Consistent with observations in
mammalian brain, these mutants displayed increased convulsant-
induced seizure activity compared to wild-type animals. Analysis
of mEPSCs recorded in vivo from intact zebrafish hindbrain neu-
rons showed that the frequency of NMDA receptor-mediated
mEPSCs was reduced in prp2−/− fish compared to controls, and
although NMDA receptor current amplitudes were the same in
both groups, NMDA receptor currents had longer decay times
in prp2−/− zebrafish. These recent observations agree with the
earlier findings of Walz and colleagues showing that mice lack-
ing PrPC were more sensitive to convulsant-induced seizures,
and significantly more PrPC-null mice died than wild-type mice
(Walz et al., 1999). However, a recent study found elevated thresh-
olds for convulsant-induced epileptiform activity in hippocampal
slices from PrPC-null mice compared to wild-type controls (Ratte
et al., 2011). The reason for this disparity in the literature remains
to be determined.
The presence of misfolded prion proteins could induce NMDA
receptor hyperfunction by preventing normal, PrPC-mediated
control of NMDA receptor activity. Indeed, there are several
examples of augmented NMDA receptor function in the pres-
ence of mutant or scrapie forms of the prion protein. It has been
demonstrated that NMDA receptor antagonists memantine and
MK-801 prevented PrPSc-induced toxicity in cultured rat corti-
cal neurons (Müller et al., 1993). Memantine also delayed death
of scrapie-infected mice (Riemer et al., 2008) and blocked the
PrPSc-induced increase in apoptosis of PrPC-expressing SH-SY5Y
neuroblastoma cells (Resenberger et al., 2011). Recently, Biasini
and co-workers revealed a role for aberrant NMDA receptor activ-
ity in the toxic effects of a prion protein lacking residues 105–125
in the central region, termed CR PrP (Biasini et al., 2013). In
this study, organotypic cerebellar slice cultures from CR PrP-
expressing mice were more susceptible to glutamate-, kainate-,
and NMDA-induced cell death compared to those from PrP+/−
controls, an effect that was rescued by overexpression of wild-type
PrPC. Notably, NMDA had a more marked effect on cell death
compared to the other treatments. These authors also observed
that CR PrP expression induces spontaneous inward currents,
which may contribute to enhanced NMDA receptor activity via
depolarization-induced relief of the Mg2+ ion block of these
receptors. Importantly, the toxic NMDA receptor-dependent
effects of CR PrP in this study were prevented by overexpres-
sion of wild-type PrPC, again supporting a neuroprotective role
of PrPC via prevention of NMDA receptor-mediated toxicity. In
another recent study, the toxicity of the misfolded form of a prion
protein fragment comprised of residues 90–231 was found to
be mediated in part by NMDA receptor-dependent excitotoxic-
ity (Thellung et al., 2013). In this study, treatment of cerebellar
granule neuron cultures for 1–3 days with the misfolded prion
protein 90–231 fragment augmented both intracellular Ca2+ lev-
els and apoptosis compared to that measured in control cells,
effects that were nearly completely abolished by NMDA receptor
blockade.
Altogether, the data obtained from studies using PrPC-null
animals suggest that there is aberrant NMDA receptor activity in
the absence of normal PrPC function, which is further supported
by the fact that exogenous expression of PrPC can prevent the
NMDA receptor-dependent toxic effects of misfolded or mutant
prion proteins. This raises the possibility of restoring PrPC-
mediated regulation of NMDA receptors in pathologies where
PrPC function is perturbed as a therapeutic intervention to con-
trol NMDA receptor-mediated toxicity. This could in theory be
accomplished by mimicking the interaction of PrPC with NMDA
receptors. To achieve this, more details regarding the molecu-
lar determinants governing the interaction of PrPC and NMDA
receptor proteins are required. Additionally, if loss of physio-
logical PrPC function results in augmented activity of certain
NMDA receptor subtypes, such as those containing GluN2D sub-
units, a thorough molecular characterization of the PrPC-NMDA
receptor interaction will allow development of targeted phar-
macotherapies to reduce hyperfunction of only those receptors
affected whose activity is aberrantly upregulated. This approach
could prevent undesired effects of blocking physiological NMDA
receptor signaling.
ABSENCE OF PrPC EXACERBATES ISCHEMIC INJURY—A
ROLE FOR NMDA RECEPTOR HYPERACTIVITY?
Given the neuroprotective effects of PrPC, it may not be surpris-
ing that absence of PrPC can exacerbate the neuronal damage
that ensues following an ischemic insult. Several studies have
demonstrated increased ischemic brain damage in PrPC-null mice
(McLennan et al., 2004; Sakurai-Yamashita et al., 2005; Spudich
et al., 2005; Weise et al., 2006; Mitteregger et al., 2007; Steele
et al., 2009). However, ischemia can induce an upregulation
of PrPC mRNA (McLennan et al., 2004; Mitsios et al., 2007;
Mitteregger et al., 2007) and protein (McLennan et al., 2004;
Weise et al., 2004; Shyu et al., 2005; Adle-Biassette et al., 2006;
Mitsios et al., 2007; Mitteregger et al., 2007), presumably as a
compensatory protective mechanism. The idea of compensatory
upregulation of PrPC expression protecting against cell death in
ischemia is supported by the findings that adenovirus-mediated
overexpression of PrPC reduced ischemia-induced infarct vol-
ume in rats (Shyu et al., 2005) and PrPC-overexpressing mice
showed smaller infarct volumes in response to ischemia than
wild-type controls (Weise et al., 2008). However, another showed
no difference in infarct sizes between wild-type and PrPC-
overexpressing mice exposed to ischemia (Spudich et al., 2005).
Of note, these studies used different PrPC-overexpressing mouse
models and times of ischemia, which could account for the
observed differences. Currently, the role of NMDA receptors in
the enhanced ischemic cell death seen in the absence of PrPC
is unknown. However, because NMDA receptor hyperfunction
contributes to cell death in ischemia (Lau and Tymianski, 2010;
Lai et al., 2014), and since NMDA receptor desensitization is
reduced in the absence of PrPC (You et al., 2012), enhanced
NMDA receptor-mediated Ca2+ influx may very well contribute
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to the increased ischemia-induced cell death that is observed in
PrPC-null mice.
Increases in extracellular glutamate concentration, such as
those seen in ischemic conditions, cause activation of both synap-
tic and extrasynaptic receptors (Hardingham and Bading, 2010;
Parsons and Raymond, 2014). Extrasynaptic NMDA receptor
activity can induce apoptotic signaling by promoting nuclear
import of FOXO transcription factor proteins (Hardingham and
Bading, 2010). FOXO3a has recently been identified as a nega-
tive regulator of the gene encoding PrPC, prnp (Liu et al., 2013),
and in this study it was shown that insulin-like growth factor-1
(IGF-1)-induced PI3K/Akt activity promoted prnp expression by
preventing nuclear import of FOXOproteins, thus inhibiting their
negative effect on prnp expression. Therefore, it is possible that
conditions where extrasynaptic NMDA receptor activity is upreg-
ulated may lead to a down-regulation of PrPC protein expression,
which may initiate a positive feedback loop of further dysregula-
tion of NMDA receptor activity and thus toxicity. Hence, even if
there is an initial protective upregulation of PrPC, this may not
be able to be sustained due to persistent activation of extrasy-
naptic NMDA receptors in the presence of prolonged elevation
of glutamate levels.
Another important observation concerns increased shedding
of PrPC in response to neurotoxic conditions (Wang et al., 2012).
PrPC shedding results from cleavage of PrPC near the C-terminal
GPI anchor, releasing full-length, soluble PrPC into the extra-
cellular milieu (Altmeppen et al., 2013; McDonald et al., 2014).
Wang and colleagues showed that upon treatment of cultured
rat cortical neurons with NMDA, soluble PrPC was released into
the culture medium, while total PrPC protein levels remained
unchanged (Wang et al., 2012). As noted earlier, our data demon-
strated that treatment with PI-PLC, which cleaves PrPC from
its GPI anchor thus releasing it from the cell surface, resulted
in persistent NMDA receptor-mediated current in cultured rat
hippocampal neurons that was similar to those seen in PrPC-
null hippocampal neurons (You et al., 2012). If loss of cell
surface anchored-PrPC results in aberrant NMDA receptor activ-
ity, one could envision a scenario where a positive feedback
loop contributes to further shedding of PrPC and enhanced
NMDA receptor currents, which would be of detriment to cells.
However, it has been suggested that PrPC shedding could serve
a protective role, especially in preventing Aβ-mediated toxic-
ity (discussed in Altmeppen et al., 2013; Beland et al., 2014).
A recent study by Beland and colleagues showed that shed PrPC
co-immunoprecipitated with Aβ (Beland et al., 2014), suggesting
that extracellular Aβ can be sequestered by shed PrPC to prevent
Aβ-induced cellular damage. As discussed below, we found that
Aβ1-42 induced a PrPC-dependent increase in steady-state NMDA
receptor current (You et al., 2012). Shedding of PrPC may thus
aid in preventing Aβ1-42-induced dysregulation of NMDA recep-
tor function. Hence, PrPC shedding may ultimately be protective
in situations where PrPC function is compromised, for exam-
ple by binding of Aβ peptides. On the other hand, shedding of
PrPC may promote aberrant NMDA receptor activity by alter-
ing desensitization kinetics that could contribute to cell death in
conditions such as ischemia where glutamate concentrations are
elevated.
There is also evidence that ischemia induces cleavage of PrPC
into its N- and C-terminal fragments, and that these cleavage
products can be neuroprotective. Mitteregger and coworkers also
observed that ischemia caused increased cleavage of PrPC, as
detected by elevated levels of PrPC C1 fragment on immunoblots
ofmouse brain homogenates (Mitteregger et al., 2007). In another
study, oxygen glucose deprivation increased the secretion of the
PrPC N1 fragment from cultured retinal ganglion cells (Guillot-
Sestier et al., 2009). Moreover, application of recombinant PrPC
N1 (PrPC residues 23–110) was able to prevent ischemia-induced
death of retinal ganglion cells (Guillot-Sestier et al., 2009). The
details of how PrPC N1 protects against ischemic cell death
were not fully explored, but the mechanism did involve a reduc-
tion of ischemia-induced caspase-3 activation and p53 expression
(Guillot-Sestier et al., 2009). An interesting possibility is that
the PrPC N1 fragment, which contains the octarepeat region
that binds copper, binds to NMDA receptors, thus providing
copper-dependent regulation of receptor desensitization. Of note,
inhibition of NMDA receptor activity has been shown to attenu-
ate death of retinal ganglion cells following ischemia-reperfusion
injury (Li et al., 2014).
Further support of a role for PrPC in protecting against
ischemic cell death comes from the work of Mitteregger and
coworkers where PrPC-null mice and mice expressing a prion
protein lacking amino acid residues 32–93 had infarcts of simi-
lar volumes (Mitteregger et al., 2007), suggesting that this region
of PrPC provides protection against ischemic injury. One rea-
son for increased ischemic injury in mice expressing this form of
prion protein could be that cleavage of this mutant would not
produce the normal PrPC N1 fragment. However, this deletion
mutant lacks the copper-binding octarepeat region of PrPC. As
mentioned previously, we found a copper-dependent regulation
of NMDA receptors that is mediated in large part through PrPC,
as demonstrated by no further augmentation of NMDA receptor
currents by copper chelation in the absence of PrPC (You et al.,
2012). Moreover, exogenous copper can protect neurons from
NMDA receptor-mediated death (Schlief et al., 2006), whereas
copper chelation induced cell death that could be prevented by
NMDA receptor inhibition (You et al., 2012). Recently, data from
in vitro experiments have revealed that copper enhances one type
of α-cleavage, termed α2-cleavage, of mouse PrPC (McDonald
et al., 2014). Copper induced α2-cleavage such that the resultant
N-terminal PrPC fragments terminate at alanine residues 116 or
117, in contrast to α1-cleavage observed in the absence of copper,
which produces PrPC N1 ending at lysine residue 109 (McDonald
et al., 2014). These observations suggest that copper levels may
regulate PrPC processing by influencing the amount and identity
of the N1 fragment produced, although the biological outcomes
of this copper-dependent differential PrPC cleavage are not yet
known. Of further interest is the finding that the prion pro-
teins carrying pathogenic mutations have decreased α2-cleavage
upon addition of copper (McDonald et al., 2014), suggesting
aberrant copper-dependent PrPC processing could be detrimen-
tal to the health of cells. These findings reveal the possibility
of copper-dependent processing of PrPC as another mechanism
contributing to regulation of NMDA receptor activity by cop-
per. Thus, copper may alter the activity of NMDA receptors in
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multiple ways: PrPC-independent control of receptor activity, as
evidenced by restoration of NMDA receptor desensitization in
PrPC-null neurons by addition of excess copper ions (You et al.,
2012); by mediating interaction of PrPC and NMDA receptors,
as shown by a decrease in the amount of GluN1 subunit that co-
precipitated with PrPC upon copper chelation (You et al., 2012);
and by influencing PrPC cleavage to generate PrPC N1 fragments,
which could bind to NMDA receptors to modulate their func-
tion. Although evidence exists for the former two mechanisms,
the latter remains to be investigated.
As mentioned previously, the activity of myelinic NMDA
receptors is increased by ischemic conditions, resulting in damage
to myelin (Micu et al., 2006). Thus, a loss of PrPC-mediated regu-
lation of NMDA currentmay not only be neurotoxic, butmay also
contribute to demyelination that has been observed in PrPC-null
mice and in mice expressing mutant prion proteins (Radovanovic
et al., 2005; Baumann et al., 2007; Bremer et al., 2010).
Aβ CAN DISRUPT PrPC-MEDIATED REGULATION OF NMDA
RECEPTOR ACTIVITY
PrPC has been shown to be a receptor for oligomeric Aβ peptides
(Lauren et al., 2009; Chen et al., 2010). Since these discoveries,
many studies have investigated the role of PrPC in the pathological
effects of Aβ (reviewed in Lauren, 2014). Overall, these findings
suggest a role for PrPC in protecting from the pathological effects
of Aβ peptides that occur in AD, although the requirement of
PrPC for Aβ-induced toxicity has been controversial, with some
investigators finding that PrPC was not required for the patho-
logical effects of Aβ (Balducci et al., 2010; Calella et al., 2010;
Kessels et al., 2010; Cisse et al., 2011). Recent findings by Nicoll
and coworkers may help to reconcile these discrepancies. Their
work showed that Aβ protofibrils, and not monomers or fibrils,
bind with highest affinity to full-length PrPC and the PrPC N1
fragment (Nicoll et al., 2013). Furthermore, protofibril-rich Aβ
preparations blocked LTP in a PrPC-dependent manner, whereas
LTP inhibition by fibrillar Aβ was independent of PrPC. These
observations underscore the need for careful characterization of
Aβ preparations in order to determine the nature of the Aβ species
used for experiments, which allow better interpretation of data
resulting from these experiments.
Notably, many studies have demonstrated that Aβ can alter
NMDA receptor function (reviewed in Rush and Buisson, 2014).
Recently, we demonstrated that PrPC is required for Aβ-induced
alterations in NMDA receptor kinetics (You et al., 2012).
Application of oligomerized Aβ1-42, which is known to be a
high-affinity copper chelator, to hippocampal neurons gave rise
to a persistent (i.e., non-desensitizing) NMDA current, similar
to what was observed in the presence of the copper chelator
BCS or in the absence of PrPC. Of note, the effects of Aβ1-42
and copper chelation on NMDA current were not additive, sug-
gesting that they acted via the same mechanism. Finally, in
neurons isolated from 5XFAD mice (a mouse model of AD),
NMDA current displayed a qualitatively similar persistent com-
ponent. Altogether, these data then suggest that Aβ-mediated
perturbation of NMDA receptor activity depends on both PrPC
and copper ions. Furthermore, the Aβ1-42-induced upregulation
of NMDA receptor activity may in part be responsible for the
Aβ1-42-mediated neurodegeneration observed in AD. If this were
the case, then why is neurodegeneration observed in 5XFAD
mice, but relatively absent in PrPC-null mice even though they
both display similar non-desensitizing NMDA receptor currents?
Slowed receptor desensitization can only manifest itself patho-
logically under conditions where there is a prolonged excess of
glutamate. It has been shown that Aβ1-42 prevents glutamate re-
uptake into neurons and glial cells (Danysz and Parsons, 2012),
and induces release of glutamate from astrocytes (Talantova et al.,
2013), which then would be expected to lead to just such an
excess of glutamate. Then, together with the slowed desensitiza-
tion kinetics of the receptor, this excess glutamate may damage
neuronal structures such as spines. In PrPC-null mice, this accu-
mulation of glutamate would not be expected to occur, thus
rendering the slowed desensitization kinetics physiologically inert
(Figure 2). Nonetheless, as we discussed earlier, there are other
pathophysiological events such as chemically-induced seizures or
ischemia that are known to lead to an accumulation of glutamate
that then causes increased brain damage in PrPC-null mice (Walz
et al., 1999; McLennan et al., 2004; Sakurai-Yamashita et al., 2005;
Spudich et al., 2005; Weise et al., 2006; Mitteregger et al., 2007;
Steele et al., 2009).
Work by Um and colleagues provides further evidence for the
requirement of PrPC on the effects of Aβ on NMDA receptor
function (Um et al., 2012). In their study, they found that phos-
phorylation of the GluN2B subunit of the NMDA receptor at
tyrosine residue 1472 was transiently increased by Aβ oligomers
in Fyn-overexpressing neuroblastoma cells and in cortical cul-
tures; longer treatment with Aβ oligomers (1–3 h) resulted in
decreased phospho-GluN2B levels, which correlated with an
increase in the level of STEP protein phosphatase. Moreover,
the Aβ oligomer-induced increase in GluN2B phosphorylation
was absent in PrPC- and Fyn-null cultures. Indeed, they found
that Aβ oligomers activated Fyn kinase in a PrPC-dependent
manner. Furthermore, brain extract from AD patients induced
Fyn activation in cultured mouse cortical neurons in a PrPC-
dependent manner, whereas extract from healthy controls did not
activate Fyn. The initial GluN2B phosphorylation was paralleled
by an increase in surface levels of GluN2B, and with longer Aβ
oligomer treatment a reduction in GluN2B surface expression
was observed; again, both PrPC and Fyn were required for these
Aβ oligomer-mediated effects on GluN2B surface expression. In
cultures from wild-type mice, pre-treatment for 15min with Aβ
oligomers significantly enhanced the NMDA-induced increase
in intracellular Ca2+ levels, whereas a 60min Aβ oligomer pre-
treatment significantly reduced the NMDA-induced Ca2+ signal;
in PrPC-null cultures, Aβ oligomers had no effect on the Ca2+
signal induced by NMDA. Thus, Aβ oligomers, acting via PrPC,
induce a transient increase then a decrease in NMDA receptor-
mediated Ca2+ influx into neurons. LDH release from cortical
cultures was increased upon 90min Aβ oligomer treatment and
no further toxicity was observed with a 72 h treatment. This
toxicity was NMDA receptor-dependent, as it was reduced by
NMDA receptor inhibition with both APV and ifenprodil, the lat-
ter being a specific GluN2B antagonist. Thus, brief exposure to Aβ
oligomers causes toxicity, likely by Ca2+ influx mediated by the
transient increase in surface localization of GluN2B-containing
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FIGURE 2 | Slowed NMDA receptor desensitization is pathological
only in conditions of prolonged excess of glutamate. Under normal
conditions (WT), glutamate homeostasis is unperturbed and prevents
glutamate accumulation, and NMDA receptors (NMDAR) undergo fast
desensitization, thus limiting calcium entry. In the absence of PrPC
(PrPC-null), NMDA receptor desensitization is slowed but glutamate
homeostasis remains unperturbed, thus limited calcium entry occurs.
However, in Alzheimer’s disease (AD), Aβ oligomers bind to PrPC and
cause slowed NMDA receptor desensitization. This, in combination with
Aβ-induced elevation of glutamate levels, for example by inhibiting
glutamate re-uptake by astrocytic glutamate transporters, leads to
enhanced calcium entry and pathology.
NMDA receptors. In this study, it was also shown that Aβ
oligomers induced spine loss in a PrPC- and Fyn-dependent man-
ner, and that the seizures and death due to status epilepticus
in a mouse model of AD were prevented by genetic deletion
of PrPC. Taken together, these data suggest that Aβ oligomers
signal through PrPC to induce aberrant Fyn activation, leading
to first an increase then later a decrease in activity of GluN2B-
containing receptors, which is ultimately deleterious to neurons.
Altogether, the recent data indicate that Aβ oligomers, by interact-
ing with PrPC, can alter both NMDA receptor kinetics (You et al.,
2012) and the signaling pathways that modulate NMDA receptor
function (Um et al., 2012).
A study by Resenberger and colleagues showed that Aβ- and
PrPSc-induced cell death of PrPC-expressing SH-SY5Y neuro-
blastoma cells were not additive, suggesting that these species act
via the same pathway (Resenberger et al., 2011). Furthermore,
pre-treatment with the NMDA receptor blocker memantine pre-
vented apoptosis of PrPC-expressing SH-SY5Y neuroblastoma
cells induced by PrPSc, Aβ, and a synthetic peptide designed to
be rich in β-sheet structure. This suggests that several types of
β-sheet-containing proteins/peptides share a common mecha-
nism of toxicity, aberrant NMDA receptor activity. Thus, PrPC
could contribute to toxicity in disorders other than TSEs and AD,
possibly by mediating aberrant NMDA receptor activity in the
presence of β-sheet-rich peptides.
Of further interest is the finding that the toxicity induced
by β-sheet-rich conformers was dependent upon the N-terminal
region of PrPC andwas prevented by a soluble N-terminal domain
of PrPC (Resenberger et al., 2011). Similar protective effects of
the PrPC N1 fragment against Aβ-induced toxicity have been
observed in other studies (Beland et al., 2012, 2014; Guillot-
Sestier et al., 2012; Nieznanski et al., 2012; Fluharty et al., 2013).
This raises the possibility that increased PrPC cleavage to pro-
duce the N1 fragment is neuroprotective. Interestingly, cleavage
of PrPC was increased in a mouse model of AD (Ostapchenko
et al., 2013) and in post-mortem human AD brain (Beland et al.,
2014). Furthermore, the recent findings from Beland and cowork-
ers provide strong evidence for a protective role of the soluble
N1 fragment that is produced by α-cleavage of PrPC. In this
study, the binding of PrPC N1 and Aβ induced a conforma-
tional change that produced amorphous aggregates, the amount
of PrPC N1 in guanidine hydrochloride extracts from insolu-
ble amyloid deposits from AD brain was increased compared
to non-demented controls, and there was a significant correla-
tion between the amount of α-cleavage, which generates the N1
fragment, and duration of AD (Beland et al., 2014). Altogether,
these observations indicate that cleavage of PrPC may reduce
Aβ-mediated toxicity via N1-mediated neutralization of Aβ pep-
tides, and N-terminal fragments may be useful as a therapy to
prevent pathological effects of Aβ or other β-sheet-rich peptides,
including alterations in NMDA receptor activity.
NMDA RECEPTORS, PrPC, AND NEUROINFLAMMATION
Recent evidence has emerged that glutamatergic mechanisms
operate not only in the nervous system, but also in a wide variety
of non-neuronal cells (reviews: Gill and Pulido, 2001; Skerry and
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Genever, 2001; Hinoi et al., 2004), including in the immune sys-
tem (reviews: Boldyrev et al., 2005, 2012). GluRs, both ionotropic
and metabotropic, are highly expressed in various immune cells,
such as T cells, B cells, neutrophils, macrophages and dendritic
cells, which are thought to subserve communication between the
immune and nervous systems (review: Ganor and Levite, 2012).
Interestingly, different GluRs, or different levels of certain GluRs,
are expressed in resting and activated T cells (for review see Ganor
and Levite, 2012). In particular, NMDA receptors expressed on T
cells are involved in a wide variety of T cell functions, such as
regulation of cytokine secretion (Kahlfuβ et al., 2014), prolifera-
tion (Kahlfuβ et al., 2014), apoptosis (Affaticati et al., 2011), and
induction of reactive oxygen species (Tuneva et al., 2003).
As described above, PrPC interacts with NMDA receptors
on neurons and modulates NMDA receptor-dependent neuronal
excitability and excitotoxicity (Khosravani et al., 2008). Although
the precise functions of PrPC in immune cells remain unclear,
PrPC expression is detected in the lymphoid system (Bendheim
et al., 1992; Ford et al., 2002). Human T lymphocytes constitu-
tively express PrPC and its surface expression is influenced by the
activation state of the cells (Cashman et al., 1990; Mabbott et al.,
1997). In addition, PrPC is upregulated onmouse T cells and den-
dritic cells after activation, and the lack of PrPC increases T cell
proliferation and causes T cell over-activation in mouse (Tsutsui
et al., 2008). Therefore, PrPC may play a role as a regulator of
NMDA receptors in the immune system as we observed in the
nervous system (Khosravani et al., 2008; You et al., 2012), with a
common thread being “hyperfunction” when PrPC is absent and
cannot restrain normal physiological mechanisms.
The CNS is conventionally recognized as being “immuno-
logically privileged” (Bailey et al., 2006) and is anatomically
separated from the peripheral immune system by the presence
of the blood-brain barrier (BBB) (Xiao and Link, 1998; Weller
et al., 2009). Despite the presence of the BBB, which limits the
entry of cells and pathogens to the brain, lymphocytes can traf-
fic into the CNS to surveil the local environment (Xiao and Link,
1998; Kivisakk et al., 2003). It is increasingly recognized that the
CNS is capable of shaping the immune response (for review see
Xiao and Link, 1998); it is now clear that neuroinflammation
is a well-established hallmark of a number of neurodegener-
ative diseases, including AD, and is frequently detrimental to
neurological function (Akiyama et al., 2000; Rubio-Perez and
Morillas-Ruiz, 2012; Solito and Sastre, 2012; Cappellano et al.,
2013; Enciu and Popescu, 2013; Lynch, 2014). In the AD brain,
the inflammatory response is thought to be a secondary response
caused by an initial brain insult, which is provided by dam-
aged neurons, neurites, insoluble Aβ aggregates, and neurofib-
rillary tangles as stimuli (Akiyama et al., 2000). However, recent
evidence suggests that inflammatory mediators may stimulate
amyloid precursor protein processing, and therefore, play a role
as a driving force to establish a deleterious cycle to AD pro-
gression (Heneka et al., 2010). As described above, PrPC is a
receptor for oligomeric Aβ peptides (Lauren et al., 2009; Chen
et al., 2010; Lauren, 2014), and Aβ oligomers, acting via PrPC,
modulate NMDA receptor-mediated Ca2+ influx into neurons.
Perhaps, even soluble forms of small oligomers, may directly
stimulate PrPC and modulate NMDA receptor-mediated Ca2+
influx into immune cells to trigger signaling pathways to secrete
cytokines, reactive oxygen species, and/or regulate T cell polariza-
tion at the early stage of AD. Gaining more insight into the role
of PrPC-NMDA receptor interactions in neuroinflammation may
reveal novel approaches to visualize early AD pathogenesis and
diagnosis.
CONCLUDING REMARKS
It is becoming clear that loss of PrPC regulation of NMDA recep-
tors can result in toxicity in a variety of pathological conditions,
and that Aβ can cause aberrant activation of NMDA receptors
in a PrPC-dependent manner. The possibility of restoring the
NMDA receptor-PrPC interaction as a way to protect against exci-
totoxicity will need to be tested experimentally, and in order to
accomplish this, elucidation of the molecular details of the inter-
action between PrPC and NMDA receptors is needed. In light
of the recent findings regarding cleavage of PrPC and how this
is altered in disease, there is a need for investigation of how
physiological processing of PrPC impacts NMDA receptor activ-
ity in both health and disease. Overall, a better understanding
of the molecular mechanisms that determine how PrPC regulates
NMDA receptor function will open up new therapeutic avenues
in situations where the regulation of NMDA receptors by PrPC is
perturbed, such as in AD and prion diseases.
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